Naxitamab with frontline chemotherapy for high-risk neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of neuroblastoma or ganglioneuroblastoma, based on biopsy/pathology or tumor cells in bone marrow plus abnormal urine “catecholamine” levels
- Your neuroblastoma stage at diagnosis fits one of the “high-risk” groups (INRGSS M, MS, L1 with incomplete resection and MYCN amplification, or L2 with certain risk features), or you progressed to Stage M within set timelines
- You are 21 years old or younger at diagnosis, and older than 12 months when joining the study
- Heart, liver, and kidney tests must be strong enough (specific cutoff numbers will be checked with echocardiogram/radionuclide tests, blood tests, and eGFR or urine creatinine clearance)
- If you can become pregnant or father a child: you must use highly effective birth control from consent until 6 months after stopping treatment (and you must not be pregnant or breastfeeding)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests a personalized treatment plan for children with high-risk neuroblastoma, a type of nerve tissue cancer. It aims to improve outcomes by tailoring therapy based on each child's tumor characteristics and response to prior treatment.
This trial is for children with high-risk neuroblastoma, a type of nerve cell cancer. It tests adding a new medicine called Naxitamb to standard induction therapy to see if it works better. High-risk means the cancer is advanced or has certain aggressive features.
This trial tests a targeted antibody called naxitamab (hu3F8) for children with high-risk neuroblastoma that has come back or is hard to treat. It aims to see if this therapy can help shrink or control the cancer with an acceptable safety profile.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.